NCT02714712View on ClinicalTrials.gov

SR-BI and Antiviral Treatment Response in HCV

CompletedOBSERVATIONAL

Enrollment

309

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

August 31, 2016

Conditions

Chronic Hepatitis C

Interventions

DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks

All Listed Sponsors

lead

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

OTHER

NCT02714712 - SR-BI and Antiviral Treatment Response in HCV | Biotech Hunter | Biotech Hunter